Using my US$75m FY23 revenue estimate from the Investor Update thread and a 25% EBIT margin (upper end of company FY22 guidance but expected to expand with expanding revenue, so probably conservative) gives a FY23 EBIT estimate of US$18.75m = AUD$26.2m.
That gives a current FY23 forward PE of about 14.5X and at a price of $2.75 a forward PE of 18.1X.
With additional upside from the healthcare business not factored into these numbers, this is ridiculously cheap for a company growing revenue at 74%
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)